AstraZeneca PLC AZN

What the company does

AstraZeneca PLC is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $266.0B, based in the USA.

It employs about 96,100 people and has been listed since May 17, 1993.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.

Cheap or expensive? relatively cheap

Its price-to-earnings (P/E) is 25.6 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — relatively cheap.

Revenue is growing 6% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 14.6 — they expect higher earnings.

The average analyst price target is 206.66, 20% above the current price (their view, not ours).

The stock sits at 34% of its one-year range (0% = the low, 100% = the high).

The risks

• • Quarterly report in 5 days (2026-10-30) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 16 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (10 vs 1).
• ✅ Pays a dividend (1.9% a year).

What changed this week

Over the past week the stock rose 3.7% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial finance.yahoo.com · 2026-10-24
  What the article says

  Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--(BUSINESS WIRE)--Landmark… source ↗

• Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer finance.yahoo.com · 2026-10-24
  What the article says

  More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile WILMINGTON, Del., October 24, 2026--(BUSINESS… source ↗

• IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER finance.yahoo.com · 2026-10-24
  What the article says

  Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed… source ↗

• Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis finance.yahoo.com · 2026-10-24
  What the article says

  Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE). The Phase 3 trial showed significant and clinically meaningful improvements in EoE symptoms and endoscopic endpoints sustained through one year. Investigators reported a favorable safety profile… source ↗

• U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI finance.yahoo.com · 2026-10-23
  What the article says

  The prohibitions could cut off Big Pharma from Chinese biotechs—the source of many promising cancer treatments Continue Reading source ↗

• UK Stock Market Today: FTSE 100 Futures Edge Up On Sticky Inflation Test finance.yahoo.com · 2026-10-23
  What the article says

  The Morning Bull - UK Market Morning Update Friday, 23 Oct 2026 UK stocks are set for a cautious positive open, with FTSE 100 futures edging higher as investors focus squarely on stubborn domestic inflation. Sentiment is constructive but constrained, as the inflation backdrop complicates the rate outlook. Headline UK… source ↗

What changed since last week

• Valuation moved from "priced in line with its group" to "relatively cheap".

• New risk flag: earnings report coming up.

• The price rose 5.8% since the last summary.